IVF vs CTKB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

IVF

49.0
AI Score
VS
IVF Wins

CTKB

34.9
AI Score

Investment Advisor Scores

IVF

49score
Recommendation
HOLD

CTKB

35score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric IVF CTKB Winner
Revenue 1.64M 92.28M CTKB
Net Income -17.40M -31.02M IVF
Net Margin -1063.0% -33.6% CTKB
Operating Income -1.20M -29.86M IVF
ROE 64.0% -9.6% IVF
ROA -54.8% -6.9% CTKB
Total Assets 31.74M 446.93M CTKB
Cash 840,407 73.85M CTKB
Current Ratio 0.08 4.48 CTKB
Free Cash Flow -3.56M -5.75M IVF

Relative Price Performance (Last 90 Days)

IVF 1M: -15.3% · 3M: -37.1% CTKB 1M: +25.2% · 3M: +27.1%

Current Technical Phase

IVF

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 36

RSI (14): 35.6 · Price: $0.86

CTKB

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (6.4% over 20 days), RSI 71

RSI (14): 71.1 · Price: $5.87

Fundamentals Snapshot

Metric IVF CTKB
Market Cap — —
Forward P/E -0.1 83.9
Trailing P/E 0.0 —
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.4% 0.5%
Operating Margin -0.6% -0.3%
EPS 361.73 -0.61
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, IVF is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.